# A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

> **NCT00136461** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 40 (—)

## Conditions studied

- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** All-trans retinoic acid
- **DRUG:** Bryostatin 1

## Key facts

- **NCT ID:** NCT00136461
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-05
- **Primary completion:** 2000-08
- **Final completion:** 2000-08
- **Target enrollment:** 40 (—)
- **Last updated:** 2011-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00136461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00136461, "A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00136461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*